Intech Investment Management LLC Increases Stake in STERIS plc $STE

Intech Investment Management LLC raised its position in STERIS plc (NYSE:STE) by 183.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 44,233 shares of the medical equipment provider’s stock after acquiring an additional 28,616 shares during the period. Intech Investment Management LLC’s holdings in STERIS were worth $10,945,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in STE. Jones Financial Companies Lllp lifted its position in STERIS by 46.1% in the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 349 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of STERIS by 32.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after buying an additional 59,264 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of STERIS by 16.1% in the 1st quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 319 shares during the period. Woodline Partners LP boosted its stake in shares of STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after buying an additional 2,372 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in shares of STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after buying an additional 5,803 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Trading Up 1.1%

Shares of STE stock opened at $254.50 on Friday. The stock has a market cap of $24.96 billion, a P/E ratio of 35.50 and a beta of 1.03. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The business has a fifty day simple moving average of $255.88 and a 200-day simple moving average of $251.60.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The company’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period last year, the company posted $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s dividend payout ratio (DPR) is currently 35.15%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $275.20.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.